Prothena Corporation plc is a clinical-stage biotech company developing antibody-based therapies targeting protein misfolding diseases, particularly neurodegenerative conditions. Its lead candidates include Prasinezumab in Phase 3 trials for Parkinson's disease, Coramitug in Phase 3 for transthyretin amyloidosis, and several earlier-stage programs addressing Alzheimer's disease and other neurological disorders. The company operates through partnerships with Roche for synuclein-targeting antibodies and Bristol Myers Squibb for tau and TDP-43 targeted treatments.

entry readiness 48 · WEAK SETUP · exit proximity 0

Value area 8.24–9.45 · 76% of 120d volume overhead · heavy supply